Bayesian decision theory can be used not only to establish the optimal sample size and its allocation in a single clinical study, but also to identify an optimal portfolio of research combining different types of study design. Within a single study, the highest societal pay-off to proposed research is achieved when its sample sizes, and allocation between available treatment options, are chosen to maximise the Expected Net Benefit of Sampling (ENBS). Where a number of different types of study informing different parameters in the decision problem could be conducted, the simultaneous estimation of ENBS across all dimensions of the design space is required to identify the optimal sample sizes and allocations within such a research portfolio. ...
The Design Space (DS) is defined as the set of factors settings (input conditions) that provides res...
The International Conference for Harmonization (ICH) has released regulatory guidelines for Pharmace...
This article describes an approach to optimal design of phase II clinical trials using Bayesian deci...
Bayesian decision theory can be used not only to estab-lish the optimal sample size and its allocati...
Sample size determination (SSD) is a key issue in medical study design – in some cases (i.e. a RCT) ...
A decision maker confronted with the task of designing a clinical trial has to consider a multitude ...
The basic premise of this thesis is that Bayesian Decision Theory (BDT) can and should be used to so...
One of the most important questions in the planning of medical experiments to assess the performance...
Value of Information (VOI) methods are based on Bayesian decision theory and provide decision makers...
Pilot studies and other small clinical trials are often conducted but serve a variety of purposes an...
Current practice for sample size computations in clinical trials is largely based on frequentist or ...
Medical research has evolved conventions for choosing sample size in randomized clinical trials that...
We show how mutually utility independent hierarchies, which weigh the various costs of an experiment...
Statistical design of experiments allows for multiple factors influencing a process to be systematic...
The design of randomised controlled trials (RCTs) entails decisions that have economic, as well as s...
The Design Space (DS) is defined as the set of factors settings (input conditions) that provides res...
The International Conference for Harmonization (ICH) has released regulatory guidelines for Pharmace...
This article describes an approach to optimal design of phase II clinical trials using Bayesian deci...
Bayesian decision theory can be used not only to estab-lish the optimal sample size and its allocati...
Sample size determination (SSD) is a key issue in medical study design – in some cases (i.e. a RCT) ...
A decision maker confronted with the task of designing a clinical trial has to consider a multitude ...
The basic premise of this thesis is that Bayesian Decision Theory (BDT) can and should be used to so...
One of the most important questions in the planning of medical experiments to assess the performance...
Value of Information (VOI) methods are based on Bayesian decision theory and provide decision makers...
Pilot studies and other small clinical trials are often conducted but serve a variety of purposes an...
Current practice for sample size computations in clinical trials is largely based on frequentist or ...
Medical research has evolved conventions for choosing sample size in randomized clinical trials that...
We show how mutually utility independent hierarchies, which weigh the various costs of an experiment...
Statistical design of experiments allows for multiple factors influencing a process to be systematic...
The design of randomised controlled trials (RCTs) entails decisions that have economic, as well as s...
The Design Space (DS) is defined as the set of factors settings (input conditions) that provides res...
The International Conference for Harmonization (ICH) has released regulatory guidelines for Pharmace...
This article describes an approach to optimal design of phase II clinical trials using Bayesian deci...